Malignant Pleural Mesothelioma

This book provides health professionals and scientists with a comprehensive overview of the mesothelioma - an asbestos induced malignancy. It includes chapters on epidemology, diagnosis, histopathology, radiology, surgery, chemotherapy, immune therapy, and radiotherapy as well as the molecular biology and future therapies.

This book provides essential information on recent advances in molecular genetics, epidemiology, translational research, and the latest results of clinical trials on mesothelioma. Significant progress has been made in understanding mesothelioma biology, and in developing new therapies for this refractory tumor, malignant pleural mesothelioma (MPM). Not only does this volume summarize the latest research-based data on the disease; it also shares insights into future research directions. The book consists of 5 themed sections on: epidemiology, pathogenesis, screening and early detection, molecular genetics, and clinical aspects and management. Several chapters focus on new trends in the field, e.g. immune therapy and identification of biomarkers, molecular oncogenesis including genetic susceptibility, and molecular diagnostic pathology. The book also highlights new cancer treatment approaches, such as immunotherapy based on immune checkpoint inhibitors, which has meant a paradigm shift in other types of cancer, and given some hope to MPM patients. In turn, it discusses recent molecular pathological studies on mesothelioma, which claim to offer more accurate classifications than traditional morphology and immunohistochemistry-based approaches. All of these cutting-edge analyses provide the basis for a closing discussion on future developments and research directions. Malignant Pleural Mesothelioma - Advances in Pathogenesis, Diagnosis, and Treatments has been edited and authored by respected researchers and will be of interest to medical, surgical and radiation oncologists; pulmonologists; pathologists and basic researchers alike. Since the disease represents a significant diagnostic and therapeutic challenge, scientists and clinicians from learners to experts, as well as fellows in training in these subspecialties, will value this book.

Malignant mesothelioma is an aggressive and fatal neoplasm of serous membranes that still shows a rising incidence worldwide. This book covers all the important aspects of the disease by bringing together contributions from selected experts in the fields of epidemiology, imaging, pathological diagnosis, therapy, genetics, and screening. Special emphasis is placed on the latest diagnostic techniques and current therapy standards. In addition, the mineralogy of asbestos is reviewed and clear advice is included on the analysis of tissue mineral fiber content. By providing a compact, scientifically based, and up-to-date overview of the management of malignant mesothelioma, this volume will be invaluable for all clinicians and pathologists who are engaged in the diagnosis and treatment of the disease or in related research.

[OFFICIAL CURRENT VERSION] From the National Comprehensive Cancer Network (NCCN) comes this essential guide to Malignant Pleural Mesothelioma. Based on clinical treatment guidelines used by doctors and oncology professionals around the world, these NCCN Guidelines for Patients help patients and caregivers talk with their doctors and make treatment decisions. Topics include: Mesothelioma basics, Tests for mesothelioma, Planning treatment, Treatment for early-stage mesothelioma, Treatment for advanced-stage mesothelioma, Supportive care and end-of-life concerns, Making treatment decisions, Words to know, NCCN Contributors, NCCN Cancer Centers, Index . Let this authoritative handbook be your guide!

Malignant Pleural Mesothelioma: A Guide for Clinicians is a practical book developed to assist clinicians, pathologist and molecular biologist in the management of malignant pleural mesothelioma (MPM). MPM represents a challenge in terms of diagnosis, staging and treatment, and to date, the optimal management of MPM patients has not yet been clearly defined - and this book is intended to be an efficient tool for these cases. The book encompasses topics such as epidemiology and surveillance evidence, multimodality imaging assessment of MPM, pathology, molecular mechanisms and treatment of such disease. Additionally, it discusses the standard operative procedures and the future directions for the management of MPM from experts' experiences. Malignant Pleural Mesothelioma: A Guide for Clinicians is a valuable source for oncologists, pathologist, cancer researchers, thoracic specialists and several members of biomedical field who needs to learn more from experts about the diagnosis, operative procedures and treatment of malignant pleural mesothelioma. Offers operative procedure sections in each chapter Brings updated information on epidemiology, molecular mechanism, diagnosis and treatment of MPM from experts of the field Provides innovative and prospective approaches for the management of mesotheliomas

Mesothelioma is an aggressive cancer with very poor survival and lack of treatment options. This book, written by a diverse panel of experts, presents a description of the most relevant topics on epidemiology, diagnosis, biomarkers, and treatment updates, including interesting discussion on molecular mechanisms, prognostic features, and novel therapies that are either approved or under clinical development for this challenging disease. It also discusses and explains genetic biomarkers, as there may be a role for some nuclear regulatory genes and proteins in development of mesothelioma, although targeted therapies so far have had limited impact.

"Mesothelioma is a type of cancer in which tumors form in the tissue that lines the lungs, heart, stomach, and other organs. While mesothelioma is relatively rare, it represents a serious health crisis as the disease is aggressive and often fatal. This book includes five chapters that detail the treatment and prognosis of the disease as well as the factors that put a person at risk for developing mesothelioma. Chapter One describes the most promising emerging immunotherapy combinations for the treatment of malignant pleural mesothelioma, discussing the biological rational underlying their development as well as the issues surrounding their clinical development. Chapter Two provides an overview of malignant mesothelioma, describing the history of its diagnosis and treatment as well as the role that asbestos exposure and other factors play in its development. Chapter Three revises the role of the main inflammatory and immunological markers as prognostic indicators in malignant pleural mesothelioma and discusses the surgical effects on immune response against cancer. Chapter Four explores the main cancer markers utilized for mesothelioma diagnosis as well as the new developments in the field. Lastly, Chapter Five examines the various surgical options available for removing pleural tumors"--

Pleural diseases are usually accompanied by pulmonary or nonpulmonary (heart, kidney, thyroid, systemic) diseases. Rarely, pleural diseases are solitary lesions. Pleural effusions are frequent manifestations of pleural diseases. Their treatment depends on the cause of effusion. Tuberculous and nontuberculous inflammation of pleura cause effusion as well as benign and malignant tumors. Talc treatment is one of the modalities of therapy for pleural effusions. Asbestosis is still the leading cause of pleural tumors. A solitary fibrous tumor of pleura is a mesenchymal tumor with various morphological patterns but with a consistent immunophenotype. A high proliferative index requires frequent follow-up because of possibe relapse and mandatory oncological treatment. A pleural malignant mesothelioma is aggressive and is the most frequent tumor of mesothelial origin. This book provides readers with a better understanding of pleural diseases, their etiology, diagnosis, and therapy

This book is a printed edition of the Special Issue "Mesothelioma Heterogeneity: Potential Mechanisms" that was published in IJMS

This issue of Thoracic Surgery Clinics, guest edited by Dr. Bryan M. Burt, is devoted to Malignant Pleural Mesothelioma. Dr. Burt has assembled expert authors to review the following topics: Biomarkers for the Diagnosis and Monitoring of Malignant Pleural Mesothelioma; Taken Together: Effective Multimodal Approaches for Malignant Pleural Mesothelioma; Pleurectomy/Decortication for Malignant Pleural Mesothelioma; Preoperative Identification of Benefit from Surgery for Malignant Pleural Mesothelioma; The Role of Extrapleural Pneumonectomy in Malignant Pleural Mesothelioma; The Molecular Basis of Malignant Pleural Mesothelioma; Radiation Therapy for Malignant Pleural Mesothelioma; The Staging of Malignant Pleural Mesothelioma; Intraoperative Adjuncts for Malignant Pleural Mesothelioma: The Fourth Dimension; The Pathology of Malignant Pleural Mesothelioma; and more!

Malignant pleural mesothelioma, a malignancy due largely to asbestos exposure, represents an increasingly common challenge to clinical and medical oncologists, respiratory physicians, and cardiothoracic surgeons, as well as researchers in the field. The disease has yet to reach its peak and is expected to kill over 100,000 people worldwide. As malignant pleural mesothelioma gains in profile, Kenneth O'Byrne and Valerie Rusch present a comprehensive overview of the subject, aimed at all health care professionals who come into contact with patients with the disease. The book includes chapters on epidemiology, diagnosis, histopathology, radiology, surgery, chemotherapy, immune therapy, radiotherapy, and palliative medicine, written by an international team of contributors. A molecular biology section focuses on the carcinogenic effects of asbestos fibres and simian virus 40, angiogenesis and angiogenic growth factors, the immune response, and genetic abnormalities detected in the disease. Future therapies are also covered, as is a perspective on the distinct legal issues related to the disease. This highly-illustrated, full colour book provides the ultimate, timely resource on this devastating disease.

Malignant Pleural Mesothelioma: A Guide for Clinicians is a practical book developed to assist clinicians, pathologist and molecular biologist in the management of malignant pleural mesothelioma (MPM). MPM represents a challenge in terms of diagnosis, staging and treatment, and to date, the optimal management of MPM patients has not yet been clearly defined – and this book is intended to be an efficient tool for these cases. The book encompasses topics such as epidemiology and surveillance evidence, multimodality imaging assessment of MPM, pathology, molecular mechanisms and treatment of such disease. Additionally, it discusses the standard operative procedures and the future directions for the management of MPM from experts’ experiences. Malignant Pleural Mesothelioma: A Guide for Clinicians is a valuable source for oncologists, pathologist, cancer researchers, thoracic specialists and several members of biomedical field who needs to learn more from experts about the diagnosis, operative procedures and treatment of malignant pleural mesothelioma. Offers operative procedure sections in each chapter Brings updated information on epidemiology, molecular mechanism, diagnosis and treatment of MPM from experts of the field Provides innovative and prospective approaches for the management of mesotheliomas

This book offers an updated review of malignant mesothelioma, including the latest advances in our understanding of its genetic control and molecular biology, as well as pre-clinical and clinical research. It also presents state-of-the-art diagnostic approaches and therapeutic options, and an open discussion on the future prospects for patient management. Malignant mesothelioma is an enormous global health problem related to asbestos exposure. Despite the best efforts of scientists and oncologists, the prognosis for those affected remains poor. Due to anatomical characteristics and non-specific symptoms, the diagnosis of mesothelioma at an early stage is often difficult, while surgery and radiotherapy are only of limited use, even if some multimodality approaches seem promising. In turn, medical treatments are sometimes successful in tumor control, but have little impact on overall survival. However, advances in our understanding of the disease’s biology, together with the availability of new drugs and combinations, make mesothelioma an essential and highly topical field for pre-clinical and clinical studies. This book is subdivided into four parts: epidemiology and preclinical data, diagnosis, therapy, and extrathoracic mesothelioma. It highlights the progress made in a variety of areas – e.g. in vitro and in vivo experimental models, genetics, environment, biomarkers, targeting agents, immunotherapy, metabolic imaging and ongoing clinical trials – and describes the standard clinical management of mesothelioma patients, including those with extra-thoracic localizations. Given its scope, the book offers an invaluable tool for researchers, oncologists and clinicians alike.

Malignant Mesothelioma brings together the most current diagnostic criteria and treatment plans from the world’s leading experts on this rare but devastating cancer. The first edition was a critical and commercial success and this revision builds on that reputation. The editors have brought together the world’s leading experts to fully explore the latest scientific breakthroughs in carcinogenesis, immunotherapy, potential vaccination strategies, and gene therapy. The clinical aspects of the book are equally strong, with thorough discussion of epidemiology, etiology, different clinical presentations, imaging (including interventional pulmonology), treatment of benign disease, strategies for multimodality treatment of malignant disease. Editors: Harvey I. Pass, M.D, Chief, Thoracic Surgery, New York University, New York, NY; Nicholas Vogelzang, M.D, Director, Nevada Cancer Institute, Las Vegas, NV; University of Chicago, Michele Carbone, M.D., Ph.D, Researcher and Director, Thoracic Oncology Program, Cancer Research Center of Hawaii, Honolulu, HI; and Anne S. Tsao, M.D, Department of Thoracic/Head & Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX.

This internationally renowned reference work is a fully updated and expanded second edition of the most comprehensive title available on pleural diseases. Building on the many strengths of the highly respected first edition, the book features a detailed yet lucid basic science section to support understanding of the physiological and pathophysiological mechanisms that underlie diseases of the pleura. This is followed by a wide-ranging series of clinical chapters, discussing both familiar and less common aspects of pleural diseases. Chapters in the clinical section are written in an accessible and uniform style, making extensive use of illustrative material and covering definition, incidence and epidemiology, etiology and pathogenesis, clinical presentation, investigations, treatments, possible complications and directions for future development. State-of-the-art scientific knowledge is presented at an appropriate level for the practicing clinician, and published management guidelines are included where relevant. Each chapter concludes with a summary of its 'key points', highlighting practical messages regarding patient management for the reader. Textbook of Pleural Diseases is an indispensable reference for pulmonary physicians and trainees worldwide.